STI podcast BMJ Group

Today we talk about transmission, diagnosis and management of MPox. We will also review the UK community and the World Health’s Organization's perspective on this virus. Please note that after the recording of this podcast the WHO implemented a change of the name of the virus to MPox.

Dr Fabiola Martin, STI's Podcast editor, interviews Dr Liesbeth Van Gestel, ID physician and clinical researcher at the Tropical Institute of Antwerp, Belgium; Mr Simon Collins, director and co-founder of HIV iBase London, UK; as well as Dr Meg Doherty, the World Health Organisation’s Director of Global HIV, Hepatitis and STIs Programmes.

For more information, please read the STI recently published articles: one from Vanhamel and co-authors tracking the transmission of the virus in the early phases of the outbreak in Belgium (https://sti.bmj.com/content/early/2022/11/17/sextrans-2022-055601), and a second from Heskin and colleagues reporting on the rapid response of sexual health services to the outbreak in the UK (https://sti.bmj.com/content/early/2022/12/14/sextrans-2022-055558?rss=1).

In this double-interview podcast, the Editor-in-Chief of the STI journal, Professor Anna Maria Geretti, brings you some of the highlights from the HIV Glasgow 2022 conference.
In the first interview (starting at 1:00), Professor Geretti interviews Jean-Michel Molina*, who discusses HIV and STI prevention.
The second interview (starting at 12:30) is with Professor Miłosz Parczewski**. They discuss the effects of the war in Ukraine on the country’s healthcare system, in particular on the prevalence of STIs.

*Professor of Infectious Diseases University of Paris, France and Head of the Infectious Diseases Department, Saint-Louis Hospital and Lariboisière Hospital Paris, France.

**Clinical specialist and Professor of Infectious Diseases Pomeranian Medical University, Szczecin, Poland. Associate Editor on STI and newly elected Vice President of the European AIDS Clinical Society.

To hear more episodes of the STI Podcast, please subscribe:
https://podcasts.apple.com/gb/podcast/sti-podcast/id356342980

Today we talk with the principal investigators of the DoxyPEP trial which was prematurely terminated due to its amazing success: participants receiving a stat dose of Doxycycline 200mg in less than 72 hours after condom-less sex were 63% less likely to develop a bacterial STI compared to participants in the control arm.
Prof Annie Leutkemeyer based in San Francisco (UCSF) and Prof Connie Celum, based in Seattle (WA)join Dr Fabiola Martin, STI's Podcast editor, in this short interview.

Please listen to a recent podcast on the wider subject of Bacterial STIs: https://soundcloud.com/bmjpodcasts/management-of-bacterial-stis?in=bmjpodcasts/sets/sti

Related links:
https://www.aidsmap.com/news/jul-2022/taking-antibiotic-after-sex-cuts-stis-two-thirds-doxypep-study-finds
academic.oup.com/cid/article/70/6/1247/5557867
www.ncbi.nlm.nih.gov/pmc/articles/PMC8360665/

To hear more episodes of the STI Podcast, please subscribe: https://podcasts.apple.com/gb/podcast/sti-podcast/id356342980

Today we focus on presumptive and prophylactic management of bacterial STIs, talking with Dr Manoji Gunathilake, Head of sexual health services in Darwin, Australia, and Assistant Prof Will Nutland, the director of the NGO, the Love Tank, in London, UK.
Related links:
STI Guidelines Australia: https://sti.guidelines.org.au/
The Love Tank: http://thelovetank.info/
GRASP report: data to June 2021 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1033882/GRASP_2020_Report.pdf
Taking antibiotic after sex cuts STIs by two-thirds, ‘DoxyPEP’ study finds - www.aidsmap.com/news/jul-2022/tak…xypep-study-finds
Doxycycline PEP significantly reduces STIs in people at high risk of infections - i-base.info/htb/43528

In this podcast, we interview Professor Joel Palefsky about the ANCHOR study. Sexually Transmitted Infections' Editorial Fellow, Dr Ming Lee, speaks to the journal Editor in Chief, Professor Anna Maria Geretti, and Professor Palefsky, chief investigator of the randomised controlled trial, about the study which investigated treatment of anal high-grade squamous intraepithelial lesions (HSIL) to prevent progression to anal cancer.
The study was stopped early following an interim analysis showing a clear benefit in reducing the risk of progression to anal cancer by 57 %, and the findings were recently published in the New England Journal of Medicine. Professor Palefsky also discusses how screening for anal cancer could be improved.
Related link about the ANCHOR study: https://www.nejm.org/doi/10.1056/NEJMoa2201048?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Thank you for joining us for the HTLV2022 Conference review. Dr Fabiola Martin speaks to Joanna Curteis, the Australian patient representative, Dr Carolina Rosadas, researcher associate at National Centre for Human Retrovirology, Imperial College London, who specialises in HTLV-1 vertical transmission and Prof Damian Purcell. Damian's research group investigates the HIV-1 and HTLV-1 human retroviruses that cause AIDS and leukaemia/inflammatory pathogenesis respectively at Doherty Institute, Melbourne. We also discuss the Global Call to Action towards the elimination of HTLV-1 and an important message from the World Health Organisation delivered by Dr Meg Doherty.
Related blog post: https://blogs.bmj.com/sti/2022/07/06/ichr-2022/
Related links:
https://www.htlvnet.com
https://www.htlvaware.com
HTLV Channel https://www.youtube.com/channel/UCI6aLSTtk7chXMeybJ92Fhw
Follow @HTLVChannel
National Centre for Human Retrovirology http://www.htlv.eu/
WHO HTLV technical report https://apps.who.int/iris/handle/10665/339773